Abstract
Neurodegenerative disorders are due to excessive neuronal apoptosis and the caspase-3 plays a key role in the apoptotic pathway. The caspase-3 inhibition may be a validated therapeutic approach for neurodegenerative disorders and an interesting target for molecular modeling studies using both Ligand and structure based approaches. In view of the above we have generated the Ligand based pharmacophore model using the Discovery studio 2.0 software. In addition to this a structure based approach has been used to validate the developed pharmacophoric features to gain a deeper insight into its molecular recognition process. This validated pharmacophore and the docking model was then implemented as a query for pharmacophore based virtual screening to prioritize the probable hits for the Caspase-3. Two ligands, ZINC12405015 and ZINC12405043 were finally selected on the basis of their fit values and docking scores. This study also reveals the important amino acids viz. His-121, Ser-205, Arg-207 which were found to be playing crucial role in the binding of the selected compounds within the active site of caspase-3.
Keywords: Caspase-3, docking, multi-neurodegenerative disorders, virtual screening.
CNS & Neurological Disorders - Drug Targets
Title:Identification of Potent Caspase-3 Inhibitors for Treatment of Multi- Neurodegenerative Diseases Using Pharmacophore Modeling and Docking Approaches
Volume: 13 Issue: 8
Author(s): Khurshid Ahmad, Vishal M. Balaramnavar, Mohammad H. Baig, Ashwini K. Srivastava, Saif Khan and Mohammad A. Kamal
Affiliation:
Keywords: Caspase-3, docking, multi-neurodegenerative disorders, virtual screening.
Abstract: Neurodegenerative disorders are due to excessive neuronal apoptosis and the caspase-3 plays a key role in the apoptotic pathway. The caspase-3 inhibition may be a validated therapeutic approach for neurodegenerative disorders and an interesting target for molecular modeling studies using both Ligand and structure based approaches. In view of the above we have generated the Ligand based pharmacophore model using the Discovery studio 2.0 software. In addition to this a structure based approach has been used to validate the developed pharmacophoric features to gain a deeper insight into its molecular recognition process. This validated pharmacophore and the docking model was then implemented as a query for pharmacophore based virtual screening to prioritize the probable hits for the Caspase-3. Two ligands, ZINC12405015 and ZINC12405043 were finally selected on the basis of their fit values and docking scores. This study also reveals the important amino acids viz. His-121, Ser-205, Arg-207 which were found to be playing crucial role in the binding of the selected compounds within the active site of caspase-3.
Export Options
About this article
Cite this article as:
Ahmad Khurshid, Balaramnavar M. Vishal, Baig H. Mohammad, Srivastava K. Ashwini, Khan Saif and Kamal A. Mohammad, Identification of Potent Caspase-3 Inhibitors for Treatment of Multi- Neurodegenerative Diseases Using Pharmacophore Modeling and Docking Approaches, CNS & Neurological Disorders - Drug Targets 2014; 13 (8) . https://dx.doi.org/10.2174/1871527313666141023120843
DOI https://dx.doi.org/10.2174/1871527313666141023120843 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Aging and Remodeling During Healing of the Wounded Heart: Current Therapies and Novel Drug Targets
Current Drug Targets MicroRNAs: Novel Diagnostic and Prognostic Biomarkers in Atherosclerosis
Current Topics in Medicinal Chemistry Transient Receptor Potential Channels - Emerging Novel Drug Targets for the Treatment of Pain
Current Medicinal Chemistry Diabetic Cardiomyopathy: Electromechanical Cellular Alterations
Current Vascular Pharmacology Ammonium Activates Ouabain-Activated Signalling Pathway in Astrocytes: Therapeutic Potential of Ouabain Antagonist
Current Neuropharmacology Thienopyridines in Percutaneous Coronary Interventions: Standard Procedures and High Risk Subsets
Current Pharmaceutical Design Cardiovascular Effects of EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibodies
Cardiovascular & Hematological Agents in Medicinal Chemistry Statins and Vulnerable Plaque
Current Pharmaceutical Design Chagas Disease Chemotherapy: What Do We Know So Far?
Current Pharmaceutical Design Editorial: (Thematic Issue: Novel Strategies for Cardiac Repair Post-Myocardial Infarction)
Current Pharmaceutical Design Endogenous Cardioprotective Agents: Role in Pre and Postconditioning
Current Drug Targets Monoamine Receptors in the Regulation of Feeding Behaviour and Energy Balance
CNS & Neurological Disorders - Drug Targets Novel Targets for Cardiac Antiarrhythmic Drug Development
Current Pharmaceutical Design Stem Cell Transplantation in Pediatric Leukemia and Myelodysplasia: State of the Art and Current Challenges
Current Stem Cell Research & Therapy Oxidative-Nitrosative Stress as a Contributing Factor to Cardiovascular Disease in Subjects with Diabetes
Current Vascular Pharmacology Postponing Motherhood: A Demographic and Contemporary Issue
Current Women`s Health Reviews Cellular Mechanisms for Diastolic Dysfunction in the Human Heart
Current Pharmaceutical Biotechnology The Challenges of Blood Pressure Control in Dialysis Patients
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Refined Purification of Large Amounts of Rat cvHsp/HspB7 and Partial Biological Characterization In Vitro
Protein & Peptide Letters Radionuclide Imaging in Patients with Ischemic Heart Failure
Current Medical Imaging